• Co-founder and executive chair of the board of directors of EIP Pharma, Inc.
• Member of the board of directors of Revvity Inc. and F2G Ltd.
• Advisor to Sofinnova Telethon Fund.

• President of Human Genetic Therapies Shire PLC, 2007-2013.
• Executive chair of IDM Pharma Inc., 2006-2007.
• President and chief executive officer in GlycoFi Inc., 2003-2004. 

• Considered independent under the Danish Corporate Governance Recommendations.
• Member of the Board of Directors since March 2015. Most recently elected in 2023 for a term of one year.
• Member of the Audit Committee since March 2015. The Board has assessed that Ms Grégoire qualifies as independent pursuant to the US Securities Exchange Act.
• Member of the Research & Development Committee since March 2017.
• Member of the Nomination Committee since March 2018.

• Global corporate leadership.
• Healthcare and pharma industry.
• Medicine & science.
• Finance & accounting.
• Business development, M&A and external innovation sourcing.
• Human capital management.

• 1986: Pharmacy Doctorate degree, the State University of NY at Buffalo, US,
• 1984: BA in Pharmacy, Laval University, Canada.
• 1980: Science College degree, Séminaire de Sherbrooke, Canada.

Canadian and American, born 1961. Female.